Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W60Y | ISIN: NL0010583399 | Ticker-Symbol: CSUA
Tradegate
16.02.26 | 16:17
21,280 Euro
-0,19 % -0,040
Branche
Nahrungsmittel/Agrar
Aktienmarkt
AMX
1-Jahres-Chart
CORBION NV Chart 1 Jahr
5-Tage-Chart
CORBION NV 5-Tage-Chart
RealtimeGeldBriefZeit
21,32021,38016:48
21,32021,38016:48
GlobeNewswire (Europe)
657 Leser
Artikel bewerten:
(2)

Corbion joins the Ferment4Health Project to unlock the gut health potential of fermented foods

DATE June 13, 2025

Corbion joins the Ferment4Health Project to unlock the gut health potential of fermented foods

Ferment4Health, led by Wageningen University, will explore the health benefits of fermentation through cutting-edge research.

Corbion, the sustainable specialty ingredients company, has joined forces with Wageningen Food & Biobased Research and five other international partners in the newly launched Ferment4Health project. This public-private research initiative aims to uncover how fermented foods and postbiotics can improve gut health and reduce chronic low-grade inflammation, a key factor in many lifestyle-related diseases.

Fermented foods like yogurt, kefir, and kimchi are widely consumed for their digestive and immune-system benefits, but scientific validation of these claims remains limited. Ferment4Health seeks to bridge that gap by combining cutting-edge research with real-world applications. The project will explore how bioactive compounds formed during fermentation, including postbiotics, interact with the gut microbiome and immune system.

"We are proud to contribute our expertise in fermentation and sustainable food solutions to this groundbreaking initiative, said Domenico Vulcano, VP Global Innovation and R&D at Corbion. "We believe that science-backed innovation is essential to creating healthier, more sustainable food systems."

As part of the consortium, Corbion will help translate scientific findings into next-generation functional food solutions. The company's lactic acid and algae-based lipids, such as Omega-3 DHA, are already recognized for their role in supporting health. Through Ferment4Health, Corbion aims to expand its portfolio of health-promoting ingredients rooted in sustainable fermentation science.

The project is co-funded by the Dutch Top Sector Agri & Food and Top Sector Life Sciences & Health, and includes partners Kerry, Ani Biome, Medex, Puratos, and CNIEL. Together, the consortium will apply a multidisciplinary approach - from in vitro cell models to human clinical trials - to assess the impact of fermented products on intestinal health and inflammation. The aim is to ultimately promote knowledge-driven product development in line with growing consumer interest in gut health and sustainable food solutions.
"This initiative is a unique opportunity to connect academic research with industrial innovation," said project manager Lonneke Janssen Duijghuijsen of Wageningen Food & Biobased Research. "By understanding how fermentation products support health, we can help to develop the next generation of functional foods."

For more information, please contact:

Press:
Lucas Wiarda, Strategic Marketing Director Health & Nutrition
+31(0)6 10334360

Analysts and investors:
Alex Sokolowski, Head of Investor Relations
+31(0)6 46941365

Background information:

Corbion is a sustainable ingredients company dedicated to preserving what matters, including food and food production, health, and the planet. We specialize in lactic acid, lactic acid derivatives, food preservation solutions, functional blends, and algae ingredients, using our deep application and product knowledge to propel nature's ingenuity through science. With more than a century of experience, we continue working side-by-side with our customers to make our cutting-edge technologies work for them. Leveraging our advanced capabilities in fermentation and preservation technology, we help customers differentiate their products in diverse markets ranging from food and animal nutrition to home & personal care, pharmaceuticals, electronics, medical devices, and bioplastics. In 2024, Corbion generated annual sales of € 1,332.0 million with a workforce of 2,399 FTEs. Corbion is listed on Euronext Amsterdam. For more information: www.corbion.com


© 2025 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.